Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Business Wire
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company’s management team will participate in two upcoming conferences.8th Annual Evercore Healthcare ConferenceDate:December 2, 2025Time:8:45-9:05 am ETFormat:Fireside ChatParticipant:Dr. Arun Swaminathan, Ph.D., Chief Executive OfficerLocation:Miami, FLWebcast:https://wsw.com/webcast/evercore52/coya/2359192Coya’s management team will be available for one-on-one meetings during the Evercore Conference for interested parties.18th Clinical Trials on Alzheimer's Disease (CTAD) ConferenceDate:December 2, 2025Time:3:10-3:50 pm ETFormat:Roundtable Discussion Titled “Charting the Path Forward for Combination Therapy in Alzheimer’s Disease: Challenges, Considerations, and Collaborative Solutions”Participant:Dr. Fred Grossm
Show less
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to StockholdersBusiness Wire
- Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.MarketBeat
- Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia PatientsBusiness Wire
- Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.MarketBeat
- Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)Business Wire
COYA
Earnings
- 11/12/25 - Miss
COYA
Sec Filings
- 1/20/26 - Form 8-K
- 1/8/26 - Form 8-K
- 1/6/26 - Form 4
- COYA's page on the SEC website